Assessing the binding interaction of polystyrene sulfonate with amitriptyline in healthy volunteers: a cross-over design — The BIND study
Authors:
- 16 February 2022
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (5) , 839-845
Abstract
Purpose Polystyrene sulfonate is used for binding potassium in patients with chronic kidney disease (CKD). Because of its binding properties, it can potentially bind other medications and thereby decrease their bioavailability and effectiveness. Amitriptyline, often used by CKD patients for neuropathic pain, shows significant binding to polystyrene sulfonate in vitro. The purpose of this study was to determine the effect of polystyrene sulfonate on the exposure of amitriptyline in vivo when taken concomitantly in healthy volunteers. Methods We performed a prospective cross-over study in nine healthy volunteers. Participants were 18 years of age or older, did not use any medication, and had no known allergy to amitriptyline or polystyrene sulfonate. Participants visited Deventer Teaching Hospital twice. Once they received a single dose of amitriptyline 50 mg and once they received a single dose of both polystyrene sulfonate 15 g and amitriptyline 50 mg taken concomitantly, with a wash out period of at least 1 week. After intake of the medication, six blood samples were collected, at 2, 3, 4, 5, 6, and 8 h. Blood samples were analysed to determine maximum concentration (Cmax) and area under the curve 0–8 h after intake (AUC0–8 h). Difference in Cmax and AUC0–8 h was analysed with a paired T-test or Wilcoxon signed rank test, depending on normality of the data. A p-value < 0.05 was considered statistically significant. Results Of the nine participants included, eight participants completed both visits to the hospital. Mean maximum concentration (Cmax) of amitriptyline was 35.61 µg l−1 (95% CI 27.90–43.33 µg l−1) when taken alone, compared to 9.25 µg l−1 (95% CI 6.59–11.92 µg l−1) when taken with polystyrene sulfonate (p < 0.001). Mean AUC0–8 h of amitriptyline was 168.20 µg × h l−1 (95% CI 139.95–196.45 µg × h l−1) when taken alone and 45.78 µg × h l−1 (95% CI 30.20–61.36 µg × h l−1) when taken with polystyrene sulfonate (p < 0.0001). Conclusion These results show a significant decrease in exposure of amitriptyline of approximately 75% when taken concomitantly with polystyrene sulfonate, thereby probably compromising therapy efficacy. Patients using both amitriptyline and polystyrene sulfonate should be informed to separate intake of these medications. Trial registration NL8539 (17 April 2020).Keywords
This publication has 26 references indexed in Scilit:
- Quantitative Structure-Property Relationships Modeling to Predict In Vitro and In Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol)The Journal of Clinical Pharmacology, 2009
- Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: Impact on oral bioavailability, absorption, and metabolic disposition in ratsXenobiotica, 2006
- Drug Dosing in Chronic Kidney DiseaseMedical Clinics of North America, 2005
- Delay in gastric emptying in patients with chronic renal failureScandinavian Journal of Gastroenterology, 2004
- Concomitant administration of cholestyramine influences the absorption of troglitazoneBritish Journal of Clinical Pharmacology, 1998
- Drug Interaction between Simvastatin and Cholestyramine in Vitro and in Vivo.Biological and Pharmaceutical Bulletin, 1996
- Cation-exchange resin and inhibition of intestinal absorption of thyroxineThe Lancet, 1993
- Effect of sodium polystyrene sulfonate on lithium bioavailabilityAnnals of Emergency Medicine, 1992
- Doxepin-Cholestyramine InteractionPsychosomatics, 1988
- Analysis of the in vitro interaction between vancomycin and cholestyramineAntimicrobial Agents and Chemotherapy, 1981